CA3183242A1 - Compositions et procedes de modulation de la transduction du signal mediee par flrt3 - Google Patents

Compositions et procedes de modulation de la transduction du signal mediee par flrt3

Info

Publication number
CA3183242A1
CA3183242A1 CA3183242A CA3183242A CA3183242A1 CA 3183242 A1 CA3183242 A1 CA 3183242A1 CA 3183242 A CA3183242 A CA 3183242A CA 3183242 A CA3183242 A CA 3183242A CA 3183242 A1 CA3183242 A1 CA 3183242A1
Authority
CA
Canada
Prior art keywords
seq
flrt3
antibody
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3183242A
Other languages
English (en)
Inventor
Dallas Benjamin Flies
Kushal Prajapati
Adem Can Koksal
Linda Liu
Solomon Langermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NextCure Inc
Original Assignee
NextCure Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NextCure Inc filed Critical NextCure Inc
Publication of CA3183242A1 publication Critical patent/CA3183242A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne des compositions et leurs procédés d'utilisation pour moduler la signalisation médiée par FLRT3. Par exemple, l'invention concerne des agents immunomodulateurs qui réduisent l'expression de FLRT3, la liaison de ligands, la réticulation, la signalisation médiée par FLRT3, ou une combinaison de celles-ci. Dans un autre mode de réalisation, l'invention concerne des agents immunomodulateurs qui améliorent ou favorisent l'expression de FLRT3, la liaison de ligands, la réticulation, la signalisation médiée par FLRT3, ou une combinaison de celles-ci. Ces agents peuvent être utilisés pour moduler la réponse immunitaire chez un sujet en ayant besoin.
CA3183242A 2020-06-18 2021-06-21 Compositions et procedes de modulation de la transduction du signal mediee par flrt3 Pending CA3183242A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063040654P 2020-06-18 2020-06-18
US63/040,654 2020-06-18
PCT/US2021/038201 WO2021258040A2 (fr) 2020-06-18 2021-06-21 Compositions et procédés de modulation de la transduction du signal médiée par flrt3

Publications (1)

Publication Number Publication Date
CA3183242A1 true CA3183242A1 (fr) 2021-12-23

Family

ID=79268748

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3183242A Pending CA3183242A1 (fr) 2020-06-18 2021-06-21 Compositions et procedes de modulation de la transduction du signal mediee par flrt3

Country Status (5)

Country Link
JP (1) JP2023530489A (fr)
CN (1) CN116322748A (fr)
AU (1) AU2021293287A1 (fr)
CA (1) CA3183242A1 (fr)
WO (1) WO2021258040A2 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
US20090304735A1 (en) * 2006-05-19 2009-12-10 Gabrielle Therese Belz Immunogenic Compositions
WO2016129627A1 (fr) * 2015-02-13 2016-08-18 国立大学法人大阪大学 Procédé de criblage pour substances soulageant la douleur, et composition pharmaceutique pour la prévention ou le traitement de la douleur
WO2017083515A2 (fr) * 2015-11-10 2017-05-18 Visterra, Inc. Conjugués molécules anticorps-médicaments et leurs utilisations
US10617773B2 (en) * 2016-08-05 2020-04-14 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
JP7303110B2 (ja) * 2017-01-18 2023-07-04 ビステラ， インコーポレイテッド 抗体分子－薬物コンジュゲートおよびその使用

Also Published As

Publication number Publication date
AU2021293287A1 (en) 2023-02-16
CN116322748A (zh) 2023-06-23
WO2021258040A2 (fr) 2021-12-23
WO2021258040A3 (fr) 2022-01-27
JP2023530489A (ja) 2023-07-18

Similar Documents

Publication Publication Date Title
US20250084164A1 (en) Compositions and methods for modulating lair signal transduction
AU2019211326B2 (en) B7-H4 antibodies and methods of use thereof
US11390675B2 (en) Antibodies for Siglec-15 and methods of use thereof
US20240076379A1 (en) Antibodies to programmed cell death protein 1
US20230357384A1 (en) Compositions and methods for modulating flrt3 mediated signal transduction
CA3183242A1 (fr) Compositions et procedes de modulation de la transduction du signal mediee par flrt3
RU2846895C2 (ru) Композиции и способы для модуляции передачи сигнала lair
RU2809243C2 (ru) Антитела в7-н4 и способы их применения
WO2025155809A2 (fr) Compositions et procédés de modulation de la transduction de signal médiée par vstm-1
HK40110799A (en) Antibodies for siglec-15 and methods of use thereof
EP4360714A2 (fr) Anticorps pour siglec-15 et leurs procédés d'utilisation
HK40010180A (en) Antibodies for siglec-15 and methods of use thereof
HK40010180B (en) Antibodies for siglec-15 and methods of use thereof

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250521

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250521

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250613

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250613

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250807

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250807

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250807